Refeeding Syndrome in Cachectic Cancer Patients

Understanding Refeeding Syndrome

The American Society for Parenteral and Enteral Nutrition recommends that cachectic patients with obstructing lower esophageal cancer starting on preoperative TPN are at high risk for refeeding syndrome, particularly those with >20% weight loss over 3 months 1, 2
Severe malnutrition with significant weight loss (>20% over 3 months) creates a state of metabolic adaptation where the body has depleted intracellular electrolytes, increasing the risk of refeeding syndrome 1, 3
Esophageal obstruction has likely caused prolonged inadequate nutrient intake, worsening the catabolic state and increasing the risk of refeeding syndrome 4

Hypophosphatemia is the most characteristic and clinically significant electrolyte abnormality in refeeding syndrome, occurring as phosphate shifts intracellularly with glucose metabolism, with a high level of evidence from the American Society for Parenteral and Enteral Nutrition 1, 2
Hypokalemia is the second most common electrolyte disturbance in refeeding syndrome, with a moderate level of evidence from the American Society for Parenteral and Enteral Nutrition 3

Severe hypophosphatemia can lead to respiratory muscle weakness, potentially complicating post-surgical recovery, with a high level of evidence from the American Thoracic Society 4
Severe hypophosphatemia can also lead to cardiac dysfunction, including arrhythmias and heart failure, with a moderate level of evidence from the American Heart Association 3

The American Society for Parenteral and Enteral Nutrition recommends beginning TPN at no more than 25% of calculated energy requirements (approximately 20-25 kcal/kg/day for bedridden patients) to prevent refeeding syndrome, with a high level of evidence 1, 5
Monitoring serum phosphate, potassium, and magnesium levels daily for the first week of TPN is recommended to prevent refeeding syndrome, with a moderate level of evidence from the American Society for Parenteral and Enteral Nutrition 3
Prophylactically supplementing phosphate before and during initial TPN administration is recommended to prevent hypophosphatemia, with a high level of evidence from the American Society for Parenteral and Enteral Nutrition 4, 6

Cancer cachexia involves cytokine-induced metabolic alterations that prevent normal nutrient utilization, as noted by Clinical Nutrition 7

Neurological complications can occur due to severe hypophosphatemia in refeeding syndrome, as reported in Clinical Nutrition 8
Cancer patients with intestinal obstruction often have expansion of extracellular water volume, which is not associated with hypernatremia, according to Clinical Nutrition 8